Seikagaku Reports FY 3Q18 Revenue of ¥7,330MM, -11.1% vs. FY 3Q17

Seikagaku posted FY 3Q18 revenue of ¥7,330MM (USD $64.7MM), -11.1% vs. FY 3Q17, as the company continues to deal with the impact from reduced drug prices as mandated by the NHI in Japan. The price reduction has filtered through to bottom line earnings as Seikagaku was able to lower administrative and general expenses, but still experienced...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us